To some, Anne Wojcicki is an “eternal optimist”, says the Financial Times – a medical industry pioneer who “won’t give up on her dream of using DNA kits to discover new drugs”. But, following the descent of the once high-flying 23andMe into bankruptcy protection, plenty of others aren’t quite so charitable. After repeated attempts to take the ailing genetics-testing firm she co-founded private, Wojcicki has now resigned as CEO to pursue an “independent” bid, amid plenty of sniping.
The rancour of shareholders is understandable. In 2008, Wojcicki used “her charm and Silicon Valley connections” to orchestrate a series of celebrity-studded “spit parties” publicising her new DNA-testing start-up, says the FT. The stars “dutifully filled 23andMe’s test tubes with their saliva”. Wojcicki’s “relentless optimism and charisma” helped “wave aside customer privacy fears and regulatory scrutiny”.
Over nearly two decades, some 15 million people splashed out for the $99 kit to learn more about their ancestry or health. “Many now appear to regret that decision.” Recently, both the company’s website and its wobbly shares crashed as customers rushed to delete their genetic data before it goes up for auction. The shares have lost 99% of their value since 2021, when 23andMe went public via a “blank cheque” company owned by Richard Branson, and became “a $6 billion unicorn”. The company is already “locked in investor disputes”. The mood won’t improve if Wojcicki secures the assets, washed clean by the Chapter 11 bankruptcy process, at a bargain price.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Who is Anne Wojcicki?
The Wojcicki family is the closest that Silicon Valley gets to a royal clan. Anne’s sister Susan, the former YouTube CEO who died last year, famously rented her Menlo Park garage to Google co-founders Larry Page and Sergey Brin – the latter became Anne’s husband (they divorced in 2015). A third sister, Janet, is a professor of paediatrics at the University of California.
The sisters grew up in an intensely academic environment, says Business Insider. Their father, Stanley, chaired Stanford’s physics department; their mother, Esther, was an influential journalist and teacher, sometimes dubbed the “Godmother” of the Valley. Anne Wojcicki credits her parents with conferring “a taste of freedom” as well as scientific inquiry – honed by “a childhood roaming around” the Stanford campus.
After graduating from Yale with a biology degree, Wojcicki headed for Wall Street and spent a decade working as a biotech and healthcare analyst. “Weary” of Wall Street’s avaricious approach to healthcare, she “decided to disrupt the industry”, says BusinessWomen. The founding aim of 23andMe, which began life in 2006, was to empower people “to take control of their well-being”. Named after the 23 pairs of chromosomes in the human genome, the start-up swiftly became “a trailblazer in personal genomics”. The kit was Time’s “Invention of the Year” in 2008, and Wojcicki was later named by Fast Company as one of America’s most “daring CEOs”.
Too daring, perhaps, says Fortune. 23andMe presents a bad case of overreach. Having built one of the world’s largest DNA databases, it began leveraging the data in 2015 – moving into “the staggeringly expensive business of drug development”. Ultimately, the retail side of the business wasn’t enough to cover costs. Already ailing, the firm was nearly torpedoed by a high-profile hack in 2023, from which it has never really recovered. From the outset, Wojcicki had bold visions and is known for her persistence, says the FT. But rebuilding the company seems a long shot.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Spending Review: what does it mean for your money?Chancellor Rachel Reeves’s Spending Review will see some departments’ budgets rise, but others won’t be quite as lucky. We look at what has been announced, and what it could mean for your money.
-
Divorce financial settlement fights surge – why it pays to agree terms earlyLawyers expect more court battles as tax rises and sharp falls in asset values make divorcing financially more difficult.
-
Mohammed bin Salman: The new face of Saudi ArabiaUnder the crown prince Mohammed bin Salman, Saudi Arabia's de facto ruler, the kingdom has pursued ambitious reforms to transform itself into a thriving 21st-century economy
-
Can Pope Leo plug a worrying black hole in the Vatican’s finances?Pope Leo, the new head of the Catholic Church, takes responsibility not just for 1.4 billion souls, but also for a complex multinational business in deep financial trouble.
-
Doug and Mary Perkins: Specsavers’ clear-sighted foundersHelped by the deregulation of the sector in the 1980s and brilliant advertising, Mary Perkins and her husband Doug have taken Specsavers to the top of the optometry market
-
Cash in on the biotech boom with three promising European picksOpinion Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d put their money
-
Greg Abel: Warren Buffett’s heir takes the throneGreg Abel is considered a safe pair of hands as he takes centre stage at Berkshire Hathaway. But he arrives after one of the hardest acts to follow in investment history, Warren Buffett. Can he thrive?
-
Who will be the next Warren Buffett?Opinion There won’t be another Warren Buffett. Times have changed, and the opportunities are no longer there, says Matthew Lynn.
-
Lorne Michaels: the ringmaster at Saturday Night LiveLorne Michaels created Saturday Night Live, a cultural phenomenon that launched the careers of countless stars in America.
-
Precision-engineered profits: How to invest in genomicsDevelopments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals. Smart investors should buy in now, says Matthew Partridge
